Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 261-874-9 | CAS number: 59709-38-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- December 1978
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 979
- Report date:
- 1979
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- Hazleton Manual of Standard Operating Procedures as applied to ICI Ltd., Central Toxicology Lahoratory procedure number CT20-90, Rat acute oral toxicity test; (HLE protocol no. 548/1).
- GLP compliance:
- no
- Remarks:
- Pre-dates GLP
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Methyl N-[4-[(2-bromo-6-chloro-4-nitrophenyl)azo]phenyl]-N-(3-methoxy-3-oxopropyl)-β-alaninate
- EC Number:
- 261-874-9
- EC Name:
- Methyl N-[4-[(2-bromo-6-chloro-4-nitrophenyl)azo]phenyl]-N-(3-methoxy-3-oxopropyl)-β-alaninate
- Cas Number:
- 59709-38-5
- Molecular formula:
- C20H20BrClN4O6
- IUPAC Name:
- methyl N-[4-[(2-bromo-6-chloro-4-nitrophenyl)azo]phenyl]-N-(3-methoxy-3-oxopropyl)-β-alaninate
- Test material form:
- solid: granular
- Details on test material:
- Disperse Brown 19
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals
Thirteen male and 13 female rats of the Wistar strain, obtained from Bantin and Kingman Ltd., Grimston, Aldbrough, Nr. Hull, were used for this study. They were conditioned to the laboratory environment for not less than 6 days. On the day before dosing individual body weights were as follows: males 140 - 200 g, females 111 - 160 g. Two female animals (No. 1 - 114 g, No. 5 - 111 g) were martinally outside the body weight range stated in the protocol (115 - 160 g), but were dosed as it was thought such marginal changes would not affect the study.
Diet
With the exception of the overnight fast (for 18-20 hours before treatment) the animals were allowed free access to mains water and food (Rat and Mouse No. 1 Expanded Diet, BP Nutrition (U.K.) Ltd., Witham, Essex). The food was reintroduced immediately after dosing.
Environment
All animals were housed in a single air-conditioned room maintained at a temperature of 22 + 3°C, relative humidity 50 + 10% and exposed to natural lighting conditions. They were caged in groups of five, by sex or two by sex as appropriate in grid floor polypropylene boxes.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- A single oral dose of test article, based on the fasted body weight of the animals at the time of treatment, was administered by gavage using a metal stomach tube (14g x 8cm).
The animals were then returned to their cages for observation. - Doses:
- 250, 500, 1000, 2000, 5000 mg/kg bw (preliminary test)
5000 mg/kg bw (main test) - No. of animals per sex per dose:
- Four groups each of 4 fasted rats (2 males, 2 females) and one group of 10 fasted rats (5 males, 5 females) were dosed according to the schedule.
- Control animals:
- no
- Details on study design:
- Dose range, finding study - phase 1
Four groups each of 4 fasted rats (2 males, 2 females) and one group of 10 fasted rats (5 males, 5 females) were dosed according to the schedule. Animals were observed for mortality over the following 48 hours.
Dose range finding study -phase 2
Mortality at a level of 50% or greater in any group did not occur during phase 1 and the surviving animals in groups 1-4 were killed. The group 5 animals were retained for observation for a further 12 days.
Observations on the group 5 animals (main test)
Animals were observed for overt toxicity and mortality at ¼, 1, 2 and 4 hours after treatment and subsequently once daily for 14 days and the observations were recorded. Body weights of survivors were recorded 2, 3, 8 and 14 days after treatment. Animals dying during the working day, animals killed in extremis and animals showing signs of toxicity at the end of the observation period were subjected to necropsy to determine any macroscopic signs of abnormalities.
At the end of the observation period all surviving animals were killed.
Results and discussion
- Preliminary study:
- Mortality at a level of 50% or greater in any group did not occur during dose range finding phase 1.
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: main test (single dose 5000 mg/kg bw)
- Mortality:
- Two female animals died within 48 hours of treatment, and 1 male died within 72 hours of treatment.
- Clinical signs:
- other: Group 5 animals All male animals showed signs of lethargy within 48 hours of treatment. One male died; the remaining 4 animals appeared normal within 72 hours of treatment and throughout the remaining observation period. All female survivors appeared norm
- Gross pathology:
- Necropsy was not performed on any of the animals on test.
- Other findings:
- No further findings specified in the study report.
Any other information on results incl. tables
Mortality in the dose range finding study up to 48 hours
Dose (mg/kg) |
Mortality |
Cumulative mortality (%) |
||
Male |
Female |
Total |
||
250 |
0/2 |
0/2 |
0/4 |
0 |
500 |
0/2 |
0/2 |
0/4 |
0 |
1000 |
0/2 |
0/2 |
0/4 |
0 |
2000 |
0/2 |
0/2 |
0/4 |
0 |
5000 |
0/5 |
2/5 |
2/10 |
20 |
Mortality and signs of reaction in group 5 rats given a single-oral dose
Dosage (mg/kg) |
Observation |
Animal number and sex |
Number showing effect during |
||||||||||||||||||
Male |
Female |
Hour |
Day |
||||||||||||||||||
1 |
2 |
3 |
4 |
5 |
1 |
2 |
3 |
4 |
5 |
1 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8-14 |
||
5000 |
Body weights (g) Day 1 (Pre-fast) Day 1 (post-fast) Day 2 Day 3 Day 8 Day 14 Increment |
155 150 149 174 195 220 65 |
157 141 118 155 197 238 81 |
167 149 142 176 208 253 88 |
154 135 104 - - - - |
164 144 138 173 205 239 75 |
114 101 - - - - - |
123 107 120 126 137 157 34 |
125 112 118 129 143 170 45 |
122 111 126 131 148 168 46 |
111 102 - - - - - |
|
|
|
|
|
|
|
|
|
|
Mortality |
|
|
|
* |
|
* |
|
|
|
* |
0/10 |
0/10 |
1/10 |
2/10 |
3/10 |
3/10 |
3/10 |
3/10 |
3/10 |
3/10 |
|
Time when deaths noted (hr) |
|
|
|
72 |
|
48 |
|
|
|
24 |
|
|
|
|
|
|
|
|
|
|
|
Signs of reaction Lethargy |
+ |
+ |
+ |
+ |
+ |
|
|
|
|
|
0/10 |
0/10 |
1/9 |
5/8 |
0/7 |
0/7 |
0/7 |
0/7 |
0/7 |
0/7 |
|
Necropsy NP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NP = Not performed
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The oral LD50 (rats, gavage) was greater than 5000 mg/kg bw in a limit test. The substance is not classifiable according to CLP criteria.
- Executive summary:
This study was undertaken to determine the oral median lethal dose (LD50) of Disperse Brown 19 in rats. It was performed in accordance with Standard Operating Procedures.
Four groups each of 4 fasted rats (2 males, 2 females) and one group of 10 fasted rats (5 males, 5 females; main study) were dosed according to the schedule. Animals were observed for mortality over the following 48 hours.
Treatment schedule
Study
Dose group
Dose level
(mg/kg)
Solution concentrations
(mg/ml)
Treatment volume
(ml/kg)
Dose range finding
1
2
3
4
5
250
500
1000
2000
5000
500
500
500
500
500
0.5
1.0
2.0
4.0
10.0
Mortality at a level of 50% or greater in any group did not occur during phase 1 and the surviving animals in groups 1-4 were killed. The group 5 animals were retained for observation for a further 12 days.
Results
Two female animals died within 48 hours of treatment, and 1 male died within 72 hours of treatment.
Mortality
Dose
(mg/kg)
Mortality
Cumulative mortality
(%)
Male
Female
Total
250
0/2
0/2
0/4
0
500
0/2
0/2
0/4
0
1000
0/2
0/2
0/4
0
2000
0/2
0/2
0/4
0
5000
1/5
2/5
3/10
30
Group 5 Animals-All male animals showed signs of lethargy within 48 hours of treatment. One male died; the remaining 4 animals appeared normal within 72 hours of treatment and throughout the remaining observation period. All female survivors appeared normal throughout the observation period.
All surviving male animals showed decreases in body weight at day 3 of observation but these animals and all female survivors showed normal body weight gains at the end of the observation period.
Necropsy was not performed on any of the animals on test.
Conclusion
Following a dose range finding study in rats of the Wistar strain it was concluded that test article was relatively non-toxic and the oral LD50 was greater than 5000 mg/kg. This results was confirmed by the main study (5000 mg/kg bw).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.